Exchange: NasdaqCM Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
0.68% $2.22
Last updated: 7 aug 2022 - 23:40
TimeZone: America/New_York
FUNDAMENTALS | |
---|---|
MarketCap: | 210.69 mill |
EPS: | -0.367 |
P/E: | 0.000 |
Earnings Date: | Oct 11, 2022 |
SharesOutstanding: | 95.12 mill |
Avg Daily Volume: | 0.0448 mill |
RATING 2022-08-05 |
---|
B- |
Neutral |
RATINGDETAILS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Buy | |
Return On Asset: | Sell | |
DE: | Strong Sell | |
P/E: | Sell | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
1/21 | 2/21 | 3/21 | 4/21 | 1/22 | 2/22 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
DISCOUNTED CASH FLOW VALUE |
---|
$2.48 (11.96%) $0.265 |
Date: 2022-08-08 |
Expected Trading Range (DAY) |
---|
$ 2.11 - 2.32 ( +/- 4.70%) |
ATR Model: 14 days |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $2.22 (0.68% ) |
Volume | 0.0386 mill |
Avg. Vol. | 0.0448 mill |
% of Avg. Vol | 86.23 % |
Signal 1: | |
Signal 2: |
Theratechnologies, Inc. is a pharmaceutical company. The company is headquartered in Montreal, Quebec and currently employs 32 full-time employees. The firm addresses medical needs to promote healthy living for human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy. EGRIFTA is indicated for the treatment of excess visceral adipose tissue (VAT), as assessed by waist circumference of approximately 100 centimeters for males and approximately 90 centimeters for females. Ibalizumab is a cluster difference 4 (CD4)-directed HIV entryinhibitor, which focuses on treating multidrug resistant HIV-1 infection (MDR HIV-1). Ibalizumab binds to the second extracellular domain of the CD4 receptor. Ibalizumab has completed the Phase III trial. EGRIFTA is available in Canada and in the United States. The firm distributes EGRIFTA in the United States through RxC Acquisition.